Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 185 million

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.

The subscription price was determined to SEK 18.50 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, William Kåge and Clara Sohlberg.

 

Related

Vinge advises Umia Sweden and other owners in connection with the sale of Umia Stockholm to Sandbäckens

Umia Stockholm AB was founded in 2016 by Jonas Hedlund, Rolf Danielsson, Ronnie Ketola and Göran Karlsson, and currently has around 60 employees and a turnover of SEK 190 million (2023). The company specialises in electricity, which accounts for 70 % of its business, and ventilation. As part of the acquisition, Umia Stockholm AB will be integrated into the Sandbäckens brand in the near future.
December 11, 2024

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.
December 10, 2024

Vinge has assisted Boliden in the acquisition of the Neves-Corvo and Zinkgruvan mines from Lundin Mining

Boliden has entered into a definitive agreement with Lundin Mining to acquire the Neves-Corvo mine in Portugal and the Zinkgruvan mine in Sweden. The upfront cash consideration for the entities is USD 1,300 m plus contingent payments that can reach up to USD 150 m, on a cash and debt-free basis. The transaction, that considerably strengthens Boliden's mine production as well as internal zinc and copper concentrate supply, is subject to customary regulatory approvals.
December 10, 2024